45 / 114
45
A n a i s d o I HM T
45. Clavier, C, Senechal,Y,Vibert, S, and Potvin, L (2012).A theory-based model
of translation practices in public health participatory research. Sociology of health
& illness 34, 791-805.
46. Ramsden,VR, McKay, S, and Crowe, J (2010).The pursuit of excellence: en-
gaging the community in participatory health research. Global health promotion
17, 32-42.
47. Richman, DD,Wrin,T, Little, SJ, and Petropoulos, CJ (2003). Rapid evolu-
tion of the neutralizing antibody response to HIV type 1 infection. Proceedings
of the National Academy of Sciences of the United States of America 100, 4144-
4149.
48. Walker, LM, Huber, M, Doores, KJ, Falkowska, E, Pejchal, R, Julien, JP,
Wang, SK, Ramos, A, Chan-Hui, PY, Moyle, M, Mitcham, JL, Hammond, PW,
Olsen, OA, Phung, P, Fling, S,Wong, CH, Phogat, S,Wrin, T, Simek, MD, Koff,
WC,Wilson, I A, Burton, DR, Poignard, P, and Investigators, PGP (2011). Broad
neutralization coverage of HIV by multiple highly potent antibodies. Nature 477,
466-470.
49 Klein, F, Mouquet, H, Dosenovic, P, Scheid, JF, Scharf, L, and Nussenzweig,
MC (2013). Antibodies in HIV-1 vaccine development and therapy. Science 341,
1199-1204.
50. Liao, HX, Lynch, R, Zhou,T, Gao, F, Alam, SM, Boyd, SD, Fire, AZ, Roskin,
KM, Schramm, CA, Zhang, Z, Zhu, J, Shapiro, L, Mullikin, JC, Gnanakaran, S,
Hraber, P,Wiehe, K, Kelsoe, G,Yang, G, Xia, SM, Montefiori, DC, Parks, R, Lloyd,
KE, Scearce, RM, Soderberg, KA, Cohen, M, Kamanga, G, Louder, M K,Tran, L
M, Chen,Y, Cai, F, Chen, S, Moquin, S, Du, X, Joyce, MG, Srivatsan, S, Zhang, B,
Zheng, A, Shaw, GM, Hahn, BH, Kepler, TB, Korber, BT, Kwong, PD, Mascola,
JR, Haynes, BF, and Program, NCS (2013). Co-evolution of a broadly neutralizing
HIV-1 antibody and founder virus. Nature 496, 469-476.
51. Jardine, J, Julien, JP, Menis, S, Ota,T, Kalyuzhniy, O, McGuire,A, Sok, D, Huang,
PS,MacPherson,S,Jones,M,Nieusma,T,Mathison,J,Baker,D,Ward,AB,Burton,DR,
Stamatatos, L, Nemazee, D,Wilson, IA, and Schief,WR (2013). Rational HIV immuno-
gen design to target specific germline B cell receptors. Science 340, 711-716.
52. Mouquet, H (2014). Antibody B cell responses in HIV-1 infection.Trends in
immunology 35, 549-561.
53. Mouquet, H, Klein, F, Scheid, JF,Warncke, M, Pietzsch, J, Oliveira,TY,Velin-
zon, K, Seaman, MS, and Nussenzweig, MC (2011). Memory B cell antibodies to
HIV-1 gp140 cloned from individuals infected with clade A and B viruses. PloS one
6, e24078.
54. Marcelino, JM, Nilsson, C, Barroso, H, Gomes, P, Borrego, P, Maltez, F, Ro-
sado, L, Doroana, M,Antunes, F, andTaveira, N (2008). Envelope-specific antibody
response in HIV-2 infection: C2V3C3-specific IgG response is associated with di-
sease progression.Aids 22, 2257-2265.
55. Rocha, C, Calado, R, Borrego, P, Marcelino, JM, Bartolo, I, Rosado, L, Cava-
co-Silva, P, Gomes, P, Familia, C, Quintas, A, Skar, H, Leitner,T, Barroso, H, and
Taveira, N (2013). Evolution of the human immunodeficiency virus type 2 envelo-
pe in the first years of infection is associated with the dynamics of the neutralizing
antibody response. Retrovirology 10, 110.
56. Borrego, P, Marcelino, JM, Rocha, C, Doroana, M,Antunes, F, Maltez, F, Go-
mes, P, Novo, C, Barroso, H, andTaveira, N (2008).The role of the humoral immu-
ne response in the molecular evolution of the envelope C2,V3 and C3 regions in
chronically HIV-2 infected patients. Retrovirology 5, 78.
57. Marcelino, JM, Borrego, P, Nilsson, C, Familia, C, Barroso, H, Maltez, F, Do-
roana, M, Antunes, F, Quintas, A, and Taveira, N (2012). Resistance to antibody
neutralization in HIV-2 infection occurs in late stage disease and is associated with
X4 tropism.Aids 26, 2275-2284.
58. Barroso, H, Borrego, P, Bartolo, I, Marcelino, JM, Familia, C, Quintas,A, and
Taveira, N (2011). Evolutionary and structural features of the C2,V3 and C3 enve-
lope regions underlying the differences in HIV-1 and HIV-2 biology and infection.
PloS one 6, e14548.
59. Marcelino, JM, Borrego, P, Rocha, C, Barroso, H, Quintas, A, Novo, C, and
Taveira, N (2010). Potent and broadly reactive HIV-2 neutralizing antibodies eli-
cited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization
strategy. Journal of virology 84, 12429-12436.